Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | CEO & President | 3.17M | -- | 1967 |
| Mr. Henrik Juuel M.Sc. | CFO & Executive VP | 1.46M | -- | 1965 |
| Mr. Russell Thirsk M.Sc. | Executive VP & COO | -- | -- | 1968 |
| Mr. Rolf Sass Sørensen | Vice President of Investor Relations | -- | -- | -- |
| Nicole Seroff | Vice President Corporate Communications | -- | -- | -- |
| Mr. Jean-Christophe May M.B.A., Pharm.D. | Executive VP & Chief Commercial Officer | -- | -- | 1967 |
Bavarian Nordic A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,605
Description
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Corporate Governance
Upcoming Events
May 9, 2025 at 10:59 AM UTC
Bavarian Nordic A/S Earnings Date
Recent Events
Recent Events Information Not Available